Reata Pharmaceuticals, Inc. Appoints Geoffrey A. Block, M.D. as Vice President, Nephrology
January 07 2019 - 7:15AM
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
biopharmaceutical company, today announced the appointment of
Geoffrey A. Block, M.D., as Vice President, Nephrology.
Dr. Block, a world-renowned nephrologist, joins
Reata with over 20 years of experience conducting clinical research
and treating patients with chronic kidney disease (CKD). Dr.
Block served as the Director of Clinical Research in the Denver
Nephrology Research Division at Colorado Kidney Care/Denver
Nephrologists. Dr. Block has participated in multiple
clinical studies of bardoxolone methyl (bardoxolone), Reata’s lead
clinical candidate, and recently presented results from both the
Phase 2 CARDINAL and Phase 2 PHOENIX trials of bardoxolone in rare
forms of CKD at the American Society of Nephrology Kidney Week
2018.
“We are pleased to welcome Dr. Block, one of our
lead investigators and external advisors, to Reata,” said Colin
Meyer, M.D., Reata’s Chief Medical Officer. “In addition to
his participation in most major recent nephrology trials of
investigational agents, Dr. Block has served as principal
investigator for several Reata trials and been a key advisor to our
CKD development programs. This experience provides Dr. Block
with a unique perspective that will allow him to serve as a
critical interface between our internal development, medical
affairs, and commercial teams and the nephrology community.”
“I have participated in over 100 trials of
approved and investigational therapies for patients with CKD over
20 years of research, and believe nothing has shown the potential
to change the CKD treatment landscape like bardoxolone,” said Dr.
Block. “Across a variety of kidney diseases, bardoxolone
treatment has been associated with improved kidney function, as
opposed to just slowing the rate of progression, and it is an
incredible feeling to tell a patient that their kidney function has
improved rather than declined.”
Previously, Dr. Block served as an associate
clinical professor in Medicine at the University of Colorado Health
Sciences Center, as an attending physician at St. Joseph’s
Hospital, and as the medical director of the DaVita-Lowry
Hemodialysis Unit. Dr. Block received his medical degree from
the University of Cincinnati College of Medicine and completed his
fellowship in nephrology at the University of Michigan at Ann
Arbor.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical
company that develops novel therapeutics for patients with serious
or life-threatening diseases by targeting molecular pathways
involved in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone
and omaveloxolone, target the important transcription factor Nrf2
that promotes the resolution of inflammation by restoring
mitochondrial function, reducing oxidative stress, and inhibiting
pro-inflammatory signaling.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, and
our ability to obtain and retain regulatory approval of our product
candidates. You can identify forward-looking statements
because they contain words such as “believes,” “will,” “may,”
“aims,” “plans,” and “expects.” Forward-looking statements
are based on Reata’s current expectations and assumptions.
Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks, and changes in
circumstances that may differ materially from those contemplated by
the forward-looking statements, which are neither statements of
historical fact nor guarantees or assurances of future
performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to, (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) the potential market size and the size of the
patient populations for our product candidates, if approved for
commercial use, and the market opportunities for our product
candidates; and (iv) other factors set forth in Reata’s filings
with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K, under the caption “Risk Factors.”
The forward-looking statements speak only as of the date made and,
other than as required by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Contact:Reata Pharmaceuticals, Inc.(972)
865-2219info@reatapharma.comhttp://news.reatapharma.com
Investor Relations:Vinny JindalVice President,
Strategy(469) 374-8721ir@reatapharma.com
Media:Matt Middleman, M.D.LifeSci Public
Relations(646)
627-8384matt.middleman@lifescipublicrelations.com
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024